RSV prevention injection for infants under one year
Treatments studied
Part of Women’s health & pregnancy clinical trials.
This study tests a new injection (SIBP-A16) designed to protect infants against RSV, a common virus that can cause serious lung infections in babies. The trial will see if the injection is safe and works in both premature and full-term infants during their first RSV season.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby must be under 1 year old, either full-term or premature (born at least 29 weeks), and weigh at least 3 kilograms (about 6.6 pounds).
- Your baby should not have had RSV (a common respiratory virus) before or have an active infection at the time of the study.
- Your baby cannot have certain serious health conditions like chronic lung disease, significant congenital heart disease, or immune deficiency.
- Your baby must not have allergies to immunoglobulin products, blood products, or other protein-based medicines.
- Your baby cannot have received certain vaccines or other investigational drugs recently.
- During the study, your baby must not receive blood products or immunoglobulin products.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an inhaled form of peginterferon alpha-2b for children aged 1 to 3 years who have pneumonia caused by RSV. The goal is to see if this treatment helps them recover faster.
This study tests an experimental injection called SIBP-A16 in healthy adults to see if it is safe and how the body handles it. It helps researchers learn about the drug before testing it in people with a medical condition.
This study tests an RSV antibody shot that helps protect babies from severe RSV. It aims to see how well this preventive shot works in Aboriginal and Torres Strait Islander infants when given around 6-9 months of age.
This trial tests an experimental vaccine against respiratory syncytial virus (RSV) in children who are at high risk of serious RSV illness due to chronic medical conditions or weakened immune systems. The goal is to see if the vaccine is safe and effective in preventing RSV-related lower respiratory tract infections.
This study looks at babies in Brazil who develop breathing or cold-like symptoms, to see how well the RSV vaccine given to mothers during pregnancy protects infants from severe RSV illness. If your baby is under 1 year old and has respiratory symptoms, they may be able to join.
This study tests a new vaccine designed to protect against respiratory syncytial virus (RSV), a common virus that can cause serious lung infections. The vaccine is given as a shot, and the study will check how your immune system responds to it.
Hear when a new Respiratory Syncytial Virus (RSV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.